Oridonin upregulates PTEN through activating p38 MAPK and inhibits proliferation in human colon cancer cells

35Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Oridonin (ORI) has been reported as an antiproliferation and apoptosis-inducing natural product in various cancer cells. However,the exact molecular mechanism underlying these effects remains unclear. In the present study,we demonstrated the antiproliferation effect of ORI in HCT116 cells,and analyzed the possible molecular mechanism which mediates this effect. We found that ORI inhibits proliferation,induces cell cycle arrest and apoptosis in HCT116 cells,thus also tumor growth. Mechanically,we found that ORI has no substantial effect on mRNA expression of phosphatase and tensin homologue (PTEN),but increases the total protein level of PTEN and markedly reduces the phosphorylation of PTEN; Exogenous expression of PTEN potentiates the anticancer effect of ORI,while knockdown of PTEN attenuates it. ORI also increases the phosphorylation of p38 MAPK,and p38 MAPK-specific inhibitor reduces the antiproliferation effect ORI in HCT116 cells. Moreover,inhibition of p38 MAPK increases the phosphorylation of PTEN,and reverses ORI-induced decrease of PTEN phosphorylation. Our findings suggested that ORI may be a potential anticancer drug for colon cancer,this effect may be mediated by enhancing the function of PTEN through reducing its phosphorylation,which may be resulted from the ORI-induced activation of p38 MAPK.

Cite

CITATION STYLE

APA

Wu, Q. X., Yuan, S. X., Ren, C. M., Yu, Y., Sun, W. J., He, B. C., & Wu, K. (2016). Oridonin upregulates PTEN through activating p38 MAPK and inhibits proliferation in human colon cancer cells. Oncology Reports, 35(6), 3341–3348. https://doi.org/10.3892/or.2016.4735

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free